Lumakras (sotorasib) is a targeted therapy that helps patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Many patients ask about Lumakras in India, as it offers a precise approach to stopping cancer cell growth where other treatments have failed. The recommended dosage is 960 mg orally once daily, taken either alone for NSCLC or with panitumumab for mCRC. Tablets must be swallowed whole, with or without food. Though Lumakras is not yet approved in India, patients can legally access it through the Named Patient Program (NPP), which allows import of life-saving drugs unavailable locally. This ensures timely access to genuine medicine under regulatory compliance.
To check Lumakras availability, please call/WhatsApp: +91 93100 90915 or dial our TOLL-FREE: 1800-889-1064.
Overview
- Condition: New
